Kevin Kunzmann

A post hoc analysis of TOPCAT shows older patients with HFpEF report consistent efficacy with spironolactone, but worsening safety outcomes.

The Allergenic Products Advisory Committee voted in favor Friday to support the BLA data for what could become the first drug indicated for food allergy desensitization.

The biologic becomes the first in its drug class to be indicated for patients aged 6-11 years old with the difficult-to-treat condition.

How patterns and trends in diet and lifestyle have influenced gastroenterology health.

Obstructive sleep apnea has been consistently underdiagnosed in US populations. Are screening methods enough?

The scope and scale of kidney disease is on the rise—much like its most commonly associated conditions.

Addressing the drivers of poor sleep conditions is among the many ways a physician can treat patients without prescription.

Acadia Pharmaceuticals has announced positive findings for time to psychosis relapse in dementia patients, which resulted in the trial's early end.

Recent research advances have associated the gut's health to overall patient health. What do we know now?

How a pattern of poor sleep could begin a cycle of worsened respiratory and cardiovascular health.

Dr. Rizzo provides a look into the current methods of COPD screening, and how patient treatment potential is changed.

The approval for interstitial lung disease associated with systemic sclerosis or scleroderma makes nintedanib the first therapy for the rare condition.

A new extended trial for the liquid immunotherapy shows two-thirds of allergic children were able to consume at least 750 mg of peanut after 3-5 years.

Particle-depleted diesel exhaust may impair a person's lung function worse than just standard diesel exhaust—while also exposing them to more NO2.

Benzodiazepines are a common yet not very well understood drug class for elderly patients with insomnia.

How do at-risk exacerbation patients present, and what developing therapies could benefit them?

Initial PCSK9 inhibitor plus statin therapy helped hospitalized patients achieve LDL-C

A pair of phase 3 trials show the single-dose oral drug could have expanded benefits for influenza, just months before an sNDA ruling.

Findings from ISAR-REACT 5 show a treatment strategy involving prasugrel significantly reduces patient risk of death, myocardial infarction, or stroke when compared to the other antiplatelet therapy.

New findings from the THEMIS trial show patients with stable coronary artery disease and type 2 diabetes mellitus face major bleeding risks from the combination regimen.

The new cardiology guideline provides step-by-step detail to the currently best process of embolism diagnosis.

From surgery to pediatrics to neurology, major healthcare innovations have been borne out of sports medicine headlines.

In honor of National Suicide Prevention Week, Simon Rego, PsyD, and colleagues from Montefiore will look at suicide from a public health and clinical scope.

From yoga to over-the-counter drugs, numerous options are available for the sleep condition.

Air pollution is driving pediatric risk for lung disease. Are there therapies at hand to address it?

Investigative triple therapy PT010 from AstraZeneca has reached primary outcome results versus a pair of standard dual inhaled therapies.

CDC data show the infectious respiratory disease has been on a decline since at least 2007—though measures are still needed to address its prevalence in certain populations.

The SGLT-2 inhibitor is seeking an additional indication for primary renal outcome prevention in patients with or without type 2 diabetes.

A study comparing the LABA agent to maintenance therapy showed results supporting recent GINA recommendations for mild asthma management.

A primary investigator-led discussion will tap into how invasive procedures have become more embraced in US cardiology.